Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background While oral antidepressants reach efficacy after weeks, single-dose intravenous (i.v.) ketamine has rapid, yet time-limited antidepressant effects. We aimed to determine the efficacy and safety of single-dose i.v. ketamine augmentation of escitalopram in major depressive disorder (MDD). Method Thirty outpatients with severe MDD (17-item Hamilton Rating Scale for Depression total score ⩾ 24) were randomized to 4 weeks double-blind treatment with escitalopram 10 mg/day+single-dose i.v. ketamine (0.5 mg/kg over 40 min) or escitalopram 10 mg/day + placebo (0.9% i.v. saline). Depressive symptoms were measured using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR). Suicidal ideation was evaluated with the QIDS-SR item 12. Adverse psychopathological effects were measured with the Brief Psychiatric Rating Scale (BPRS)-positive symptoms, Young Mania Rating Scale (YMRS) and Clinician Administered Dissociative States Scale (CADSS). Patients were assessed at baseline, 1, 2, 4, 24 and 72 h and 7, 14, 21 and 28 days. Time to response (⩾ 50% MADRS score reduction) was the primary outcome. Results By 4 weeks, more escitalopram + ketamine-treated than escitalopram + placebo-treated patients responded (92.3% v. 57.1%, p = 0.04) and remitted (76.9% v. 14.3%, p = 0.001), with significantly shorter time to response [hazard ratio (HR) 0.04, 95% confidence interval (CI) 0.01-0.22, p Conclusions Single-dose i…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In terms of sustained effects, two RCTs have shown prolonged (4–6 weeks) antidepressant effects using combined intravenous (IV) (0.5 mg/kg) and oral (50 mg/day) ketamine augmentation in MDD/TRD populations [95,96].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [96]
In the citing paper
“Meta-analyses consistently support these findings [91,92,94], establishing ketamine’s AD efficacy in oral and intranasal administration, repeated dosing, an augmenting agent, and patients with treatment-resistant bipolar depression or suicidal ideation [91,94,95,96].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [96]
In the citing paper
“The persistence of the ketamine effect at six weeks of intake is not in line with previous studies10 11 31 and the related meta-analysis,12 but those three studies together analysed only 63 patients.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [31]
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 1×
“As in earlier studies (Larkin & Beautrais, 2011; Murrough et al. 2013a), psychotic and manic side-effectsweremeasured by the four items (suspiciousness, unusual thought content, hallucinations, conceptual disorganization) of the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962; Zhang et…”
RetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“…a checklist based on DSM-IV criteria at study entry (Trivedi et al. 2006); (4) severe MDD, defined as a total score of 524 on the 17-item Hamilton Rating Scale for Depression (HAMD) – Chinese version (Hamilton, 1960; Xie & Shen, 1984) and a score of 51 on item 3, suicide risk (Zhu & Zhang, 1998).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“The primary outcome was time until response, defined as a 550% reduction from the baseline 10-item Montgomery–Asberg Depression Rating Scale (MADRS) – Chinese version (Montgomery & Asberg, 1979; Zhong et al. 2011) total score.”
MethodKessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052 · cited 1×
“Major depressive disorder (MDD) is a common psychiatric disorder and leading cause of physical and mental disability (Kessler et al. 2005).”
BackgroundThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“…side-effectsweremeasured by the four items (suspiciousness, unusual thought content, hallucinations, conceptual disorganization) of the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962; Zhang et al. 1983) and the 11-item Young Mania Rating Scale (YMRS; Young et al. 1978), respectively.”
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“…side-effectsweremeasured by the four items (suspiciousness, unusual thought content, hallucinations, conceptual disorganization) of the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962; Zhang et al. 1983) and the 11-item Young Mania Rating Scale (YMRS; Young et al. 1978), respectively.”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“…effective pharmacological and psychosocial interventions exist, there is a considerable lag before clinically relevant efficacy, which further increases suicide risk and illness burden (Trivedi et al. 2006), particularly during the first days after starting antidepressants (Jick et al. 2004).”
BackgroundMethodAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 2×
“Third, similar to all previous studies (Berman et al. 2000; aan het Rot et al. 2010; Katalinic et al. 2013) except for one that used midazolam (Murrough et al. 2013a), saline was used as the inactive placebo.”
BackgroundResultRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“…(MADRS), self-rated depressive symptoms using the validated Quick Inventory of Depressive Symptomatology – Self-Report (QIDS-SR) – Chinese version (Rush et al. 2003; Liu et al. 2013), suicidal ideation (QIDS-SR item 12), as well as reported side-effects and severity of manic, psychotic and…”
MethodA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 3×
“Different from most (Zarate et al. 2006; aan het Rot et al. 2010; Murrough et al. 2013a) but not all previous studies (Lapidus et al. 2014), in this study patients receiving ketamine did not experience significantly greater, mild, transient elevations in measures of dissociative, and…”
BackgroundResultmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Furthermore, blockadeofmTORsignalingblockedketamine induction of synaptogenesis and behavioral responses in animalmodels of depression (Li et al. 2010).”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 8×
“(Murrough et al. 2013a).”
BackgroundResultInfluentialMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“…(NMDA) antagonists, such as ketamine, MK-801 (dizocilpine) and Ro25-6981, have been found to have antidepressant effects; however, compared to ketamine, the antidepressant effects MK-801 and Ro25-6981 at subanaesthetic doses were not sustained as long as those of ketamine (Maeng et al. 2008).”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Second, similar to most studies (Zarate et al. 2006; Price et al. 2009; aan het Rot et al. 2010; Diazgranados et al. 2010; Ibrahim et al. 2011), the sample size (n = 30) was relatively small in this study.”
ResultBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 1×
“Dissociative symptoms were measured by the Clinician Administered Dissociative States Scale (CADSS; Bremner et al. 1998).”
MethodZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“…that single ketamine infusion has rapid-acting antidepressant (Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015) and antisuicidal effects (Thakurta et al. 2012; Zarate et al. 2012), efforts to sustain its antidepressant response have been rather disappointing (aan het Rot et al. 2010).”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 8×
“(Murrough et al. 2013a).”
BackgroundResultInfluentialSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · cited 6×
“Treatmentresistant MDD was defined as lack of/insufficient response to 52 adequate antidepressant treatment trials in the current episode (Price et al. 2009; aan het Rot et al. 2010).”
BackgroundMethodResultInfluentialPrice, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 3×
“Treatments with rapid onset of antidepressant effects that could be maintained have great clinical implications (Price et al. 2009).”
BackgroundMethodResultAntidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 578 · cited 1×
“…effective pharmacological and psychosocial interventions exist, there is a considerable lag before clinically relevant efficacy, which further increases suicide risk and illness burden (Trivedi et al. 2006), particularly during the first days after starting antidepressants (Jick et al. 2004).”
BackgroundEfficacy of ECT in Depression: A Meta-Analytic Review
Pagnin, D., de Queiroz, V., Pini, S., & Cassano, G. B. (2004) · The Journal of ECT · doi:10.1097/00124509-200403000-00004 · Cited by 509 · cited 14×
“In the past decade, attention has focused on the glutamatergic system’s role in the pathophysiology of MDD and the mechanism of antidepressant action (O’Connor et al. 2010).”
BackgroundInfluentialA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“Different from most (Zarate et al. 2006; aan het Rot et al. 2010; Murrough et al. 2013a) but not all previous studies (Lapidus et al. 2014), in this study patients receiving ketamine did not experience significantly greater, mild, transient elevations in measures of dissociative, and…”
ResultHusain, M. M., Rush, A. J., Fink, M., Knapp, R., Petrides, G., Rummans, T., Biggs, M. M., O'Connor, K., Rasmussen, K., Litle, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0406 · Cited by 456 · cited 1×
“Electroconvulsive therapy (ECT) has more rapid antidepressant effects than standard pharmacotherapy (Husain et al. 2004), but its invasive nature and adverse cognitive effects make it usually a last treatment choice for MDD (Pagnin et al. 2004).”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 3×
“Since the first report of ketamine’s antidepressant efficacy (Berman et al. 2000). several case reports and controlled studies have been published (Aan Het Rot et al. 2012; Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015), concluding that a single infusion of low-dose intravenous (i.v.) ketamine (0.5 mg/kg ove…”
BackgroundResultInfluentialTaylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406 · cited 1×
“For example, SSRIs achieve statistically significant symptomatic improvement, which is not necessarily clinically relevant yet, by the end of 1 week at best (Taylor et al. 2006).”
BackgroundGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373 · cited 5×
“Thus, the combination of single ketamine infusion with initiation of escitalopram was able to double, if not triple the duration of significant depression symptom advantages v. placebo infusion found in previous studies (Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015).”
BackgroundResultInfluentialKetamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339 · cited 5×
“Thus, the combination of single ketamine infusion with initiation of escitalopram was able to double, if not triple the duration of significant depression symptom advantages v. placebo infusion found in previous studies (Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015).”
BackgroundResultInfluentialIbrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 1×
“…40 min) rapidly improves depressive symptoms with efficacy onset within 1-h post-infusion, peak effect sizes at 24 h, and lasting effects for depression symptom ratings of up until 5–8 days (Zarate et al. 2006; Skolnick et al. 2009; Ibrahim et al. 2012; Mathew et al. 2012; Katalinic et al. 2013).”
BackgroundBallard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286 · cited 1×
“It appears that a single ketamine infusion can improve suicidal ideation, which is likely related to, but not entirely driven by, the improvement in depression (Ballard et al. 2014).”
BackgroundScheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282 · cited 1×
“Ketamine’s antidepressant action may be explained by enhanced neuroplasticity through improved prefrontal glutamate homeostasis and sustained attenuations in default mode network connectivity and activity (Salvadore et al. 2009; Scheidegger et al. 2012).”
BackgroundSalvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 1×
“Ketamine’s antidepressant action may be explained by enhanced neuroplasticity through improved prefrontal glutamate homeostasis and sustained attenuations in default mode network connectivity and activity (Salvadore et al. 2009; Scheidegger et al. 2012).”
BackgroundKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229 · cited 1×
“Remission, defined as MADRS total score 410 (Zimmerman et al. 2004), was also assessed.”
MethodIbrahim, L., Diazgranados, N., Luckenbaugh, D. A., Machado-Vieira, R., Baumann, J., Mallinger, A. G., & Zarate, C. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.019 · Cited by 192 · cited 1×
“Second, similar to most studies (Zarate et al. 2006; Price et al. 2009; aan het Rot et al. 2010; Diazgranados et al. 2010; Ibrahim et al. 2011), the sample size (n = 30) was relatively small in this study.”
ResultNaughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190 · cited 2×
“However, although ketamine’s effect has been extended by repeated infusions, the results in relapse prevention have been less than promising (aan het Rot et al. 2010; Murrough et al. 2013b; Naughton et al. 2014).”
BackgroundReduced dorsal prefrontal gray matter after chronic ketamine use
Liao, Y., Tang, J., Corlett, P. R., Wang, X., Yang, M., Chen, H., Liu, T., Chen, X., Hao, W., & Fletcher, P. C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.030 · Cited by 145 · cited 1×
“Further, prolonged ketamine use might lead to neurotoxicity (Liao et al. 2010; Liao et al. 2011).”
BackgroundCaddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138 · cited 5×
“Thus, the combination of single ketamine infusion with initiation of escitalopram was able to double, if not triple the duration of significant depression symptom advantages v. placebo infusion found in previous studies (Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015).”
BackgroundResultInfluentialKetamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 130 · cited 2×
“Third, similar to all previous studies (Berman et al. 2000; aan het Rot et al. 2010; Katalinic et al. 2013) except for one that used midazolam (Murrough et al. 2013a), saline was used as the inactive placebo.”
BackgroundResultFrontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study
Liao, Y., Tang, J., Ma, M., Wu, Z., Yang, M., Wang, X., Liu, T., Chen, X., Fletcher, P. C., & Hao, W. (2010) · Brain · doi:10.1093/brain/awq131 · Cited by 128 · cited 1×
“Further, prolonged ketamine use might lead to neurotoxicity (Liao et al. 2010; Liao et al. 2011).”
BackgroundMetabotropic glutamate receptor 7: At the interface of cognition and emotion
O’Connor, R. M., Finger, B. C., Flor, P. J., & Cryan, J. F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.059 · Cited by 103 · cited 1×
“In the past decade, attention has focused on the glutamatergic system’s role in the pathophysiology of MDD and the mechanism of antidepressant action (O’Connor et al. 2010).”
BackgroundRapid Response with Ketamine on Suicidal Cognition in Resistant Depression
Thakurta, R. G., Das, R., Bhattacharya, A. K., Saha, D., Sen, S., Singh, O. P., & Bisui, B. (2012) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.101793 · Cited by 57 · cited 1×
“…that single ketamine infusion has rapid-acting antidepressant (Caddy et al. 2014; Fond et al. 2014; McGirr et al. 2015) and antisuicidal effects (Thakurta et al. 2012; Zarate et al. 2012), efforts to sustain its antidepressant response have been rather disappointing (aan het Rot et al. 2010).”
BackgroundLiu, J., Xiang, Y., Wang, G., Zhu, X., Ungvari, G. S., Kilbourne, A. M., Lai, K. Y. C., Zhong, B., Zhang, L., Zhang, Q., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.035 · Cited by 50 · cited 1×
“…depressive symptoms using the validated Quick Inventory of Depressive Symptomatology – Self-Report (QIDS-SR) – Chinese version (Rush et al. 2003; Liu et al. 2013), suicidal ideation (QIDS-SR item 12), as well as reported side-effects and severity of manic, psychotic and dissociative…”
MethodSelf-citationLanning, C., & Harmel, M. H. (1975) · Annual Review of Medicine · doi:10.1146/annurev.me.26.020175.001033 · Cited by 48
钟宝亮, Wang, Y., 陈红辉, & 王晓晖 (2011) · Zhonghua xingwei yixue yu naokexue zazhi · doi:10.3760/cma.j.issn.1674-6554.2011.01.032 · Cited by 25
Research works printed but not linked: 4
- 2003, Guideline for the Prevention and Treatment of Psychiatric Disorders in China
- Zhu, 1998, Manual of Rating Scales in Psychiatry, 121
- Zhang, 1983, The application of the Chinese version of the Brief Psychiatric Rating Scale (BPRS) (in Chinese), Chinese Journal of Nervous and Mental Diseases, 9, 76
- Xie, 1984, Use of the Chinese version of the Hamilton rating scale for depression in general population and patients with major depression (in Chinese), Chinese Journal of Nervous and Mental Diseases, 10, 346
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
“(21) 27 26 Outpatient Saline Major depression 26 100”
Self-citationSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
“103 records included 95 full-text articles assessed for eligibility 35 full-text articles excluded 1 animal trial 1 paediatric and adolescent population outcomes only 5 other disorders of primary interest* 1 ECT as a concomitant intervention 1 other NMDA-receptor antagonists only† 26 non-original research (ie, duplica…”
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
“trial (41), in which patients with major depression who were randomly assigned to receive a single ketamineinfusiononday1ofescitalopramtherapyexperienced a faster response comparedwith patientswho received a saline control infusion, and the benefitsweremaintained for 4weeks.”
Metadata
- Authors
- Hu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., Tian, T.-F., Wu, A.-S., Ma, X., & Wang, G.
- Affiliations
- Capital Medical University (CN)
- University of Macau (MO)
- The University of Western Australia (AU)
- Northwell Health (US)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Xiang, Y.-T.
- Wang, G.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2015-10-19
- Volume
- 46
- Issue
- 3
- Pages
- 623-635
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W1748696538
- Cited by
- 146
- References
- 45
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 15 · 2023: 12 · 2022: 17 · 2021: 19 · 2020: 19 · 2019: 14 · 2018: 15 · 2017: 14 · 2016: 5
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- escitalopram, major depressive disorder, antidepressant augmentation, rapid antidepressant response, remission, suicidal ideation, mania, treatment safety, outpatients, severe depression, time to response, time to remission, antidepressant efficacy
- MeSH terms
- Adolescent, Adult, Antidepressive Agents, China, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ketamine, Male, Middle Aged, Outpatients, Personality Inventory, Psychiatric Status Rating Scales, Severity of Illness Index, Citalopram, Proportional Hazards Models, Treatment Outcome, Kaplan-Meier Estimate, Young Adult, Self Report, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.